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ABSTRACT
Synthetic scaffolds that permit spatial and temporal
organization of enzymes in living cells are a
promising post-translational strategy for controlling
the flow of information in both metabolic and signal-
ing pathways. Here, we describe the use of plasmid
DNA as a stable, robust and configurable scaffold
for arranging biosynthetic enzymes in the cytoplasm
of Escherichia coli. This involved conversion of indi-
vidual enzymes into custom DNA-binding proteins
by genetic fusion to zinc-finger domains that specif-
ically bind unique DNA sequences. When expressed
in cells that carried a rationally designed DNA
scaffold comprising corresponding zinc finger bind-
ing sites, the titers of diverse metabolic products,
including resveratrol, 1,2-propanediol and mevalo-
nate were increased as a function of the scaffold
architecture. These results highlight the utility of
DNA scaffolds for assembling biosynthetic enzymes
into functional metabolic structures. Beyond metab-
olism, we anticipate that DNA scaffolds may be
useful in sequestering different types of enzymes
for specifying the output of biological signaling path-
ways or for coordinating other assembly-line pro-
cesses such as protein folding, degradation and
post-translational modifications.
INTRODUCTION
Metabolic engineering of microbial pathways provides a
cost-effective and environmentally benign route for pro-
ducing numerous valuable compounds, including com-
modity and specialty chemicals (e.g. biodegradable
plastics), biofuels (e.g. ethanol and butanol) and thera-
peutic molecules (e.g. anticancer drugs and antimicrobial
compounds). However, efforts to engineer new functional
biosynthetic pathways in well-characterized micro-
organisms such as Escherichia coli are still often
hampered by issues such as imbalanced pathway ﬂux, for-
mation of side products and accumulation of toxic inter-
mediates that can inhibit host cell growth. One strategy
for increasing metabolite production in metabolically en-
gineered microorganisms is the use of directed enzyme
organization [for a review see Ref. (1)]. This concept is
inspired by natural metabolic systems, for which optimal
metabolic pathway performance often arises from the or-
ganization of enzymes into speciﬁc complexes and, in
some cases, enzyme-to-enzyme channeling (a.k.a. meta-
bolic channeling) (1–3).
The most striking naturally occurring examples are
enzymes that have evolved three-dimensional structures
capable of physically channeling substrates such as tryp-
tophan synthase and carbamoyl phosphate synthase. The
crystal structures of these enzymes reveal tunnels that
connect catalytic sites and protect reactive intermediates
from the bulk solution (4,5). Other notable examples
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strates along a positively charged protein surface that leads
from one active site to the next (6), direct channeling of
substrates via thioester linkages between polyketide syn-
thase enzyme modules (7), compartmentalization of spe-
ciﬁc enzymes into small volumes within the cell in the
form of subcellular organelles (8,9) and dynamic assembly
of enzyme complexes, perhaps as a feedback mechan-
ism, to achieve a precise concentration of metabolic
product (10,11).
Inspired by these natural systems, several groups have
developed methods for artiﬁcially assembling enzyme com-
plexes to enhance the performance of biological pathways.
For example, direct enzyme fusions have been used to co-
ordinate the expression and localization of two resveratrol
biosynthetic enzymes in a manner that increased product
titers in yeast and mammalian cells (12). However, fusing
more than two enzymes may prove problematic due to
misfolding and/or proteolysis of the fusion protein. In a
notable departure from fusion proteins, Fierobe and co-
workers constructed artiﬁcial cellulosomes where selected
enzymes were incorporated in speciﬁc locations on a
protein scaffold (13). Compared to their free enzyme coun-
terparts, the resulting enzyme complexes exhibited en-
hanced synergistic action on crystalline cellulose. More
recently, Dueber et al. (14) expressed scaffolds built
from the interaction domains of metazoan signaling pro-
teins to assemble metabolic enzymes that were tagged with
their cognate peptide ligands. Signiﬁcant increases in the
production of mevalonate and separately glucaric acid
were observed in the presence of several of these scaffolds.
Along similar lines, Delebecque et al. (15) created RNA
aptamer-based scaffolds to control the spatial organiza-
tion of two metabolic enzymes involved in biological
hydrogen production. Similar to protein scaffolds,
RNA-based scaffolds increased the hydrogen output as a
function of scaffold architecture.
Here, we describe an alternative method for generating
artiﬁcial complexes of metabolic pathway enzymes that
uses DNA as the scaffold. The choice of DNA for guiding
enzyme assembly affords many advantages. First, DNA
has a highly predictable local structure. Therefore, scaf-
folds based on DNA have the potential for arranging
enzymes into a predeﬁned order with the caveat that super-
coiling of plasmid DNA could affect long-range ordering.
For example, the spatial orientation of bound proteins
may be tuned by varying the number of nucleotides
between the enzyme binding sites. Second, the in vivo sta-
bility of DNA scaffolds is largely sequence independent,
which means that numerous architectures of virtually any
sequence and length can be generated without decreasing
the availability of the scaffold. Protein- and RNA-based
scaffolds, on the other hand, are subject to issues asso-
ciated with misfolding, aggregation and susceptibility to
degradation (16–19), which may become more pro-
nounced as the scaffold designs become larger and more
complex (i.e. more difﬁcult to fold, greatly likelihood of
forming off-pathway intermediates and more potential
sites for enzymatic degradation). In fact, the folding and
stability of protein- and RNA-based scaffolds may change
from one design to the next, even for very subtle changes
to the RNA or protein sequence. Third, a large number of
different DNA-binding proteins exist in nature. Some of
them, such as zinc ﬁngers (ZFs), have modular structures
that can be engineered to bind unique DNA sequences
with nanomolar dissociation constants and discriminate
effectively against nonspeciﬁc DNA (20,21). As a result
of these and other advanced ZF selection methods
(22,23), there are already more than 700 experimentally
tested ZFs available for use with DNA scaffolds.
Relative to the seemingly limitless number of highly active
ZF domains and corresponding DNA sequences, there are
far fewer characterized protein interaction domains and
RNA-binding proteins with ultra-high afﬁnity for their
targets. One notable exception is leucine zipper interaction
domains, which have picomolar to nanomolar afﬁnities
and have been used for some scaffolding applications
(24). However, these domains may homodimerize and
even aggregate if included in the same polypeptide.
Finally, fourth, because of the similar overall fold, differ-
ent zinc ﬁnger domains have comparable in vivo folding
and stability proﬁles compared to the more structurally
diverse protein interaction and RNA-binding domains
used in earlier systems.
To test the potential of DNA scaffolds, we created
chimeras between target biosynthetic enzymes and ZF
domains that speciﬁcally bind unique DNA sequences.
When these modiﬁed enzymes were expressed in cells
carrying a DNA scaffold comprising corresponding ZF
binding domains, signiﬁcant titer enhancements for three
diverse metabolic products including resveratrol,
1,2-propanediol (1,2-PD) and mevalonate were achieved
compared to cells expressing unassembled pathway
enzymes. These results underscore the potential of DNA
scaffolds programmed with distinct protein docking sites
as a powerful new tool for assembling biological pathways
in a manner that directly impacts their output.
MATERIALS AND METHODS
Plasmid construction for biosynthetic pathways
Chimeric enzymes for the resveratrol biosynthetic pathway
were constructed by linking the genes encoding 4CL and
STS to the 30-end of the genes encoding Zif268 and PBSII,
respectively. Each construct included a GGSGGGSGGS
polypeptide linker separating the enzyme from the ZF
domain. 4CL was from Arabidopsis thaliana and STS
was from Vitis vinifera and were not codon optimized
for E. coli. Genes for Zif268 and PBSII were codon
optimized for expression in E. coli and synthesized by
GeneArt. PCR products corresponding to the coding
regions for enzymes and zinc ﬁngers were fused together
by overlap extension PCR. The Zif268-4CL PCR product
was restriction digested using XbaI and ApaI and PBSII-
STS was digested by ApaI and BamHI. Both fragments
were simultaneously ligated in XbaI/BamHI digested
pET19b vector to obtain plasmid pET-Res-ZF-Enz. The
4CL-STS fusion protein in plasmid pET28a (pET-
ResFusion) (12) was provided by Dr. Oliver Yu (DDPSC).
The genes encoding MgsA, DkgA and GldA were
PCR-ampliﬁed from E. coli MG1655 genomic DNA.
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polycistron for 1,2-PD synthesis as follows: the mgsA
gene was placed between NheI and XbaI, the dkgA gene
between XbaI and SphI, and the gldA gene between SphI
and HindIII. The same strong ribosomal binding site was
placed directly upstream of each gene in the polycistron
with an NdeI site at each start codon. To the 30-end of
mgsA, dkgA and gldA, codon-optimized versions of the
ZF triplets OZ052 (ZFa), OZ300 (ZFb) and OZ076
(ZFc) (22), were connected, respectively, by a codon
optimized L5 polylinker (TSAAA) (18). Each ZF was
appended with a C-terminal HA epitope tag. The resulting
plasmid was named pBAD-PD-ZF-Enz.
The mevalonate pathway enzymes were tethered to ZF
domains directly in the construct pRM178 (14). Here, the
linker and ligand at the 30-end of each gene was excised
and replaced exactly with the L5 linker and appropriate
ZF domains as above. ZFa was fused to AtoB, ZFb fused
to HMGS and ZFc fused to HMGR, with an HA epitope
tag introduced on the C-terminus of all proteins. The re-
sulting plasmid was named pTet-Mev-ZF-Enz.
Plasmid construction for DNA scaffolds
Primer pairs encoding Zif268 or PBSII binding sites
(Supplementary Table S1) separated by 2-, 4- or 8-bp
spacers and ﬂanked by standard Biobrick restriction
sites were annealed by 10-min incubation at 95 C and
subsequent slow cooling to room temperature. Multiple
copies of a DNA scaffold were assembled according to
standard Biobrick assembly (26) and cloned into the
high copy pSB1K3 vector (http://partsregistry.org/
Part:pSB1K3).
For ZFa, ZFb and ZFc binding sites (Supplementary
Table S1), pUC19 served as the basis for construction of
the DNA scaffold. pUC19 was completely digested with
AatII and PvuII and replaced with a polylinker containing
the following restriction sites: AatII–SacI–SpeI–XbaI–
SphI–ClaI–PvuII. DNA scaffolds were assembled using
SpeI and XbaI cohesive ends for ligation. Basic parts
were made so that scaffolds would be ﬂanked by SpeI
sites on the 50-end and XbaI sites on the 30-end.
Composite scaffolds were constructed by digesting the
backbone with XbaI and ligating an SpeI/XbaI-digested
insert at the 30-end, thus maintaining the SpeI site at the
50-end and XbaI site at the 30-end for future ligations. To
separate the binding sites, a 4- or 12-bp spacer was
employed. For 1,2-PD production, the resulting scaffolds
were subcloned into pBAD18, between the b-lactamase
and PBAD promoters, directly after the AgeI site. For
mevalonate production, the scaffolds were employed
directly from the pUC19 plasmid.
Bacterial strains, media and growth conditions
Resveratrol was produced in E. coli Rosetta (DE3) pLysS
harboring pET-Res-ZF-Enz encoding the Zif268-4CL and
PBSII-STS chimeras or pET-Res-Enz encoding 4CL and
STS without the ZF domains in the presence of a DNA
scaffold in plasmid pSB1K3. Overnight bacterial cultures
were diluted to optical density measured at 600nm (A600)
of 0.2 in 100ml 2 YT medium in shake ﬂasks and grown
at 30 C and 160rpm. At A600 of 0.8, 1mM IPTG and
0.3mM coumaric acid were added to induce gene expres-
sion and provide the substrate for resveratrol production,
respectively. Samples were taken for analysis 6h after in-
duction of the ZF-enzyme chimeras. Escherichia coli strain
W3110harboringthe pBAD-PD-ZF-Enz plasmidencoding
the ZF-enzyme chimeras and corresponding DNA scaf-
folds was used for 1,2-PD production. 1,2-PD anaerobic
fermentations were followed as described (27) with the fol-
lowing exceptions. L-Arabinose was added to 0.2% (w/v)
at the time of inoculation to induce gene expression. All
fermentations were run at 37 C, either at 200 or 250rpm,
with tubes held vertically or at a 45  angle. The 10-ml fer-
mentation mixtures were inoculated to an A600 of 0.05 with
the overnight culture. Samples were taken for analysis at
9h post-induction for Western blot analysis and 24h
post-induction for fermentation yields. Mevalonate pro-
duction was conducted as described (14) but with E. coli
DP10 cells harboring the pTet-Mev-ZF-Enz plasmid and a
pUC19-based DNA scaffold. An inducer concentration of
250nM anhydrotetracycline was used for all experiments.
Samples were taken for analysis at 25h post-induction for
Western blot analysis and 50h post-induction for
fermentation yields. Antibiotics were provided at the fol-
lowing concentrations: ampicillin, 100mg/ml; chloram-
phenicol, 25mg/ml; and kanamycin, 50mg/ml.
Product recovery and analysis
At selected time points, resveratrol was extracted from
1ml of bacterial supernatants by ethyl acetate as described
(28). Brieﬂy, supernatants were obtained after removing
bacteria from culture by centrifugation at 13000rpm.
Supernatants were acidiﬁed by 1M HCl (50ml/1ml super-
natant) and kept at  80 C until extracted twice by equal
volumes of ethyl acetate. Ethyl acetate was removed by
evaporation in vacuum evaporator and the remaining pel-
let resuspended in methanol prior to analysis by HPLC
(Thermo Finnigan). Separation was performed at 25 Co n
a stainless-steel column Hypersil ODS C18 (150 4.6mm
I.D., particle size: 5mm, Thermo) protected by
Phenomenex HPLC guard cartridge C18 as a precolumn.
Adequate separation was achieved in 35min by a gradient
elution and a mobile phase consisting of acetate buffer
with pH 5.6 (solvent A) and acetonitrile (solvent B).
Gradient elution program applied at ﬂow rate 1.5ml/
min was as follows: 5min 95% A, 15min 95–50% A,
3min 50–5% A, 5min 5% A, 2min 5–95% A and 5min
95% A. Chromatograms were monitored at 303nm
(Supplementary Figure S1a). Quantitative determination
of trans-resveratrol was performed using calibration
standards (0.1, 0.25, 0.5, 1 and 2mg/ml) prepared from a
stock solution of trans-resveratrol (99%, Sigma Aldrich)
in 50% (v/v) methanol in water. The standard solutions
were stored at  80 C. The identity of resveratrol was also
conﬁrmed by MS analysis (Supplementary Figure S1b).
1,2-PD present in the fermentation media was recovered
by removal of cells and quantiﬁed as described (27) with
the following exceptions. Compounds were measured
with a Waters Breeze HPLC system (Supplementary
Figure S2a). The mobile phase was a 0.03 N sulfuric
Nucleic Acids Research,2012, Vol.40, No. 4 1881acid solution, with a ﬂow rate of 0.45ml/min, and the
column and detector temperatures were 50 C and 40 C,
respectively. All samples were ﬁltered through 0.22-mm-
pore-size membranes prior to analysis. Mevalonate was
recovered by acidifying cell cultures to form mevalonol-
actone followed by extraction with ethyl acetate exactly as
described elsewhere (14). The samples were then run on
Agilent Technologies chiral cyclosil-B column (30m
length 0.25mm i.d. 0.25mm Film) to determine the
relative abundance of mevalonolactone as described in
detail elsewhere (14) (Supplementary Figure S2b).
Western blot analysis
Escherichia coli Rosetta (DE3) cells co-expressing the
Zif268-4CL and PBSII-STS chimeras or expressing the
4CL-STS fusion for 6h were harvested by centrifugation.
Likewise, W3110 cultures expressing the 1,2-PD ZF-
enzyme chimeras for 9h or DP10 cultures expressing the
mevalonate ZF-enzyme chimeras for 25h were harvested
by centrifugation. Cell pellets were resuspended in PBS,
lysed via sonication and centrifuged at 16000rpm for
10min. The supernatant was retained as the soluble cell
lysate. All samples were normalized to the amount of total
soluble protein. Immunoblot analysis of soluble lysates
was performed with anti-His antibodies (Sigma) to
detect Zif268-4CL, PBSII-STS or 4CL-STS chimeras
and anti-HA antibodies (Sigma) for detection of 1,2-PD-
or mevalonate-related chimeras according to standard
procedures. GroEL served as a loading control and was
detected with anti-GroEL antibodies (Sigma).
RESULTS
Targeting DNA in vitro and in vivo with ZF domains
We aimed to use plasmid DNA as a scaffold onto which
cellular proteins of interest could be docked (Figure 1).
This required a method for site-speciﬁc targeting of
enzymes along the DNA surface. To this end, we
focused on ﬁve different ZF domains (PBSII, Zif268,
ZFa, ZFb and ZFc) that were each comprising three
ﬁngers with speciﬁcity for unique 9 base-pair DNA se-
quences (22,29–32) (Supplementary Table S1). The selec-
tion criteria for choosing these particular ZF domains was
as follows: ﬁrst, the ZF domain should be non-toxic to the
host cells (33); second, the ZF domains should be capable
of binding orthogonal sequences with high afﬁnity. Based
on our estimation of approximately 127 plasmids per cells
(0.2mM) and approximately 5000 enzyme chimeras/cell
(8mM) (Supplementary Figure S3a), we determined that
the zinc ﬁngers should have sub-mM afﬁnity. The ﬁve ZF
domains tested here all bind DNA with low nanomolar
afﬁnity. An additional design goal was to balance fusion
protein stability with the number of competitive binding
sites in the E. coli genome. We observed that zinc ﬁngers
comprising as many as four ﬁngers did not impact the
stability or activity of the protein to which they were
fused (Supplementary Figure S3b). Of these, we focused
our attention on three-ﬁnger designs because these were
relatively short (84–87 amino acids in length) and minim-
ally cross-reactive with host DNA (only approximately 15
predicted binding sites in the E. coli genome).
Importantly, none of the selected ZF domains were pre-
dicted to bind functional regions of essential genes in
E. coli and thus would be unlikely to hamper bacterial
ﬁtness.
As a ﬁrst test of the system components, we veriﬁed
DNA binding of candidate ZF domains fused to the N-
or C-terminus of different model proteins including frag-
ments of the yellow ﬂuorescent protein (YFP) and E. coli
maltose-binding protein (MBP). Following puriﬁcation
from E. coli, all ZF chimeras bound their target DNA
sequences when positioned either N- or C-terminally
(Supplementary Figure S3c and d). Next, we determined
whether ZF domains could bind to neighboring sites on a
DNA scaffold. For this, we genetically fused split YFP to
the N- and C-termini of the ZF domains PBSII and
Zif268, respectively. As expected, reassembly of split
YFP did not occur in solution in the absence of a DNA
scaffold, or in the presence of a DNA scaffold where the
binding sites for the neighboring pairs were scrambled.
However, we observed strong ﬂuorescence indicative of
YFP reassembly in the presence of a DNA scaffold
that contained neighboring binding sites for PBSII and
Zif268 separated by only two DNA base pairs (bp)
(Supplementary Figure S4a). Binding of these PBSII and
Zif268 chimeras to the same DNA scaffold was independ-
ently conﬁrmed using surface plasmon resonance (SPR)
(Figure S4b). Taken together, these results indicate that
(i) the expression and/or activity of different target pro-
teins was not signiﬁcantly affected when fused with these
relatively small ZF domains, (ii) ZF domains retained
DNA binding activity when fused to different proteins
and (iii) two orthogonal ZF domains can simultaneously
bind their target sequences in a DNA scaffold and bring
their fused protein domains into close proximity as
evidenced by the YFP reassembly.
As a ﬁnal test, we investigated whether these ZF
domains could bind their cognate DNA targets in vivo.
To conﬁrm target DNA binding by ZFs in vivo, we gene-
rated a simple b-galactosidase (b-gal) screen for ZF
activity in E. coli. The assay involved a single, low-copy
plasmid encoding a synthetic promoter, PSYN, into which
a DNA-binding sequence speciﬁc for each ZF domain was
inserted (between 35 and 10 sites of the promoter). This
promoter was positioned upstream of the lacZ reporter
gene, expression of which was controlled by PSYN. The
gene encoding the ZF domain was cloned in the same
plasmid but under control of the arabinose inducible
PBAD promoter. The principle of this screen is that an
active ZF domain should bind to its speciﬁc target
sequence in the PSYN promoter and act as a synthetic re-
pressor, thereby decreasing the basal activity of this
promoter and lowering b-gal levels. As expected, induc-
tion of each ZF domain resulted in a strong reduction of
b-gal activity, whereas b-gal activity was unchanged in
controls where the PSYN promoter contained a binding
site of an unrelated zinc ﬁnger (Supplementary Figure
S4c). These results conﬁrm that the ZF domains used in
our studies bind speciﬁcally to their corresponding DNA
target sites in vivo and thus are ideally suited for directing
diverse cellular enzymes to speciﬁc sites on plasmid DNA.
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presence of DNA scaffolds
We next investigated the ability of the ZF domains to
assemble the resveratrol (trans-3,5,40-trihydroxystilbene)
biosynthetic enzymes on DNA in the cytoplasm of
E. coli. The metabolic pathway for this natural plant
product has been reconstituted in microbes (12,28,34).
Production of trans-resveratrol from 4-coumaric acid
occurs in two steps in which 4-coumaric acid is converted
to 4-coumaroyl-CoA by 4-coumarate:CoA ligase (4CL)
and trans-resveratrol is formed by condensation of one
molecule of 4-coumaroyl-CoA and three molecules of
malonyl-CoA by stilbene synthase (STS) (Supplementary
Figure 2a). We hypothesized that successful DNA-guided
assembly of this simple metabolic pathway would lead to
measurable increases in resveratrol titers compared to the
unassembled pathway. To test this notion, genes encoding
4CL and STS were fused to the Zif268 and PBSII ZF
domains, respectively, in one plasmid while the DNA
scaffold was present on a second plasmid. It should be
noted that a large number of possible enzyme arrange-
ments on plasmid DNA are possible. The different archi-
tectures tested here are described as [E1a:E2b]n for a
two-enzyme system, where a and b describe the enzyme
stoichiometry within a single scaffold unit [hereafter
denoted as (a:b)] and n is the number of times the
scaffold unit is repeated in the plasmid (Figure 1a). For
resveratrol assembly, we initially focused on a simple (1:1)
scaffold unit that was repeated 16 times on the plasmid
(n=16). The rationale for this number of repeats was
based on the fact that plasmid DNA copy numbers in
E. coli are commonly far below that of overexpressed
metabolic enzymes. Thus, we predicted that most simple
scaffold units would need to be repeated tens of times on a
plasmid to accommodate all of the expressed enzymes.
When the plasmids for a (1:1)16 resveratrol system were
combined in E. coli, we found that resveratrol production
was consistently enhanced by 2- to 3-fold compared to the
case where a random scaffold control plasmid was present
(Figure 2b).
In addition to enzyme stoichiometry, additional degrees
of freedom of the DNA scaffold system include the
number of repetitive scaffold units and the spacer length
between the ZF binding sites. In the case of the (1:1)16
resveratrol system, the largest product enhancement was
observed for spacer lengths of 2 and especially 8bp, while
a spacer length of 4bp showed a smaller yet measureable
improvement over the unscaffolded enzymes (Figure 2b).
An even larger increase in titer enhancement of nearly
5-fold was observed when the number of scaffold repeats
was decreased from 16 to 4 (Figure 2b). These improve-
ments highlight the ability to impact resveratrol
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E1 a E2 b E3 c
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1
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E1 E2
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(b)
Figure 1. DNA scaffold-assisted assembly of metabolic pathways in E. coli.( a) Schematic of the (1:1)n system developed for resveratrol biosynthesis.
Depicted are a representative DNA scaffold (n=1) (left) and the plasmid pET-Res-ZF-Enz for expression of the ZF-enzyme chimeras (right). E1
and E2 are the enzymes 4CL and STS, respectively, while ZF domains a and b are Zif268 and PBSII, respectively. (b) Schematic of different scaffold
arrangements used for the three-enzyme pathways producing either 1,2-PD or mevalonate. E1, E2 and E3 are the 1,2-PD or mevalonate biosynthetic
enzymes (see the text for details) and the ZF domains a, b and c are ZFa, ZFb and ZFc, respectively. In all cases where n>1 (bottom right), the
scaffolds were designed such that the ﬁrst enzyme was always ﬂanked on both sides by the second and third enzyme giving rise to a bidirectional
pathway arrangement. Also shown is the plasmid pBAD-PD-ZF-Enz or pTet-Mev-ZF-Env for expressing 1,2-PD or mevalonate ZF-enzyme
chimeras, respectively (top right). All enzymes and ZF domains were connected by ﬂexible polypeptide linkers.
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lead in some cases to optimal arrangements of the enzymes
on the DNA. Next, we examined whether the enhanced
product titers were dependent upon the close proximity
(2–8bp) of the two pathway enzymes. To test this notion,
the ZF binding sites within the (1:1)4 scaffold were sep-
arated on the plasmid by either 2bp or 850bp. The latter
conﬁguration provided the same number of binding sites
on the plasmid for both enzymes but prevented the bound
enzymes from localizing in close proximity to one another.
It is important to note here that no changes were made to
either of the chimeric enzymes. As would be expected for a
proximity effect, the 5-fold enhancement in resveratrol
production observed for the (1:1)4 scaffold was abolished
when the binding sites for each enzyme were positioned far
apart on the plasmid (Figure 2b).
We also evaluated an alternative strategy for enzyme
co-localization using a 4CL-STS fusion protein which
was previously reported to increase resveratrol production
in yeast up to  6-fold (12). In E. coli, however, the (1:1)16
scaffold system produced >50 times more resveratrol than
the 4CL-STS fusion (Figure 2b), even though bacterial
growth was very similar in both cases and the 4CL-STS
fusion protein was expressed at an equal or slightly higher
level than both the ZF-enzyme chimeras (Figure 2c). This
result may be due to the propensity of multidomain fusion
proteins to misfold (and hence be less active) in E. coli (18)
and highlights the advantage of the DNA assembly
strategy whereby each of the ZF-enzyme fusions fold
independently.
Improving the metabolic performance of a three-enzyme
pathway for 1,2-PD
To test the generality of our approach, we next focused
our attention on a three-enzyme pathway for producing
1,2-PD from dihydroxyacetone phosphate (DHAP)
(Figure 3a). We chose this pathway because a biosynthetic
route for 1,2-PD in E. coli is well established (27). For
targeting the 1,2-PD metabolic pathway enzymes to
DNA, we fused methylglyoxal synthase (MgsA),
2,5-diketo-D-gluconic acid reductase (DkgA) and glycerol
dehydrogenase (GldA) (all from E. coli) to the N-termini
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Figure 2. Enhancement of trans-resveratrol biosynthesis in the presence of DNA scaffolds. (a) Schematic representation of resveratrol biosynthetic
pathway. (b) Comparison of resveratrol titers from E. coli cells expressing the 4CL-STS fusion or Zif268-4CL and PBSII-STS chimeras in the
presence of DNA scaffolds (n=16) with different spacer lengths between ZF binding sites or a random scaffold control plasmid. Cells expressing the
ZF-enzyme chimeras in the presence of the random scaffold control served as the control to which all data was normalized. Also shown are data for
the separated (1:1)4 scaffold where the spacing between the ZF binding sites was 850bp. Samples were taken 6-h post-induction. The amount of
resveratrol produced in random scaffold control cells was 2.31±0.20mg/l. Data are the average of three replicate experiments and error bars are the
standard error of the mean (SEM). (c) Western blot of enzyme levels in cells expressing the 4CL-STS fusion protein compared to cells co-expressing
the Zif268-4CL and PBSII-STS chimeras.
1884 Nucleic Acids Research, 2012,Vol.40, No. 4of ZFa, ZFb and ZFc, respectively. For the scaffold de-
sign, target DNA sequences corresponding to each of the
ZF domains were placed on the same plasmid as the
ZF-enzyme chimeras. Given that there are approximately
127 plasmids per cell and approximately 5000 ZF-enzyme
chimeras per cell (Figure S3a), DNA scaffolds for the
three-enzyme pathway were designed that would provide
enough binding sites to accommodate all of the expressed
enzymes. Speciﬁcally, we constructed and tested scaffolds
with enzyme:scaffold ratios in the range of 40:1 to 1:3
[(1:1:1)1 to (1:4:2)32, respectively]. Like the resveratrol
results above, E. coli with the (1:1:1)16 1,2-PD system
produced  3.5 times more 1,2-PD than cells expressing
the ZF-enzyme fusions in the presence of no scaffold or
a random scaffold control (Figure 3b). Moreover, the
growth rate of the cells in all of these cases was nearly
identical. Also similar to the resveratrol results was the
observation that protein fusions including MgsA-DkgA,
DkgA-GldA and MgsA-DkgA-GldA did not improve
1,2-PD titers over the unscaffolded enzymes (data not
shown). Interestingly, when the number of scaffold unit
repeats, n, was reduced from 16 to 4, 1,2-PD titers
increased to approximately 4.5-fold above the un-
scaffolded controls. Here, only a small drop-off in meta-
bolic performance was observed when the spacing between
ZF binding sites was reduced from 12 to 4bp for the
(1:1:1)4 scaffold.
To systematically investigate the relationship between
scaffold design variables and product formation, we
generated a matrix of additional plasmid-encoded DNA
scaffolds where a was always 1, while b and c were varied
to give the following stoichiometries: 1:1:1, 1:2:1, 1:2:2,
1:4:1 and 1:4:2. The number of scaffold units, n, was varied
to be 1, 2, 4, 8, 16 or 32 and the spacing between ZF
binding sites was either 4 or 12bp. It should also be
noted that the ﬁrst pathway enzyme, MgsA, was ﬂanked
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Figure 3. DNA scaffold-assisted production of 1,2-PD. (a) Schematic representation of 1,2-PD biosynthetic pathway. (b) Comparison of 1,2-PD
titers from E. coli cells expressing the MgsA-ZFa, DkgA-ZFb and GldA-ZFc chimeras in the presence of a (1:1:1)n scaffold with n=4 or 16 and the
spacing between ZF binding sites=4 or 12bp as indicated. Cells expressing the ZF-enzyme chimeras in the presence of no scaffold served as the
control to which all data were normalized. Also shown are data from cells carrying a random scaffold control. The amount of 1,2-PD produced in
unscaffolded control cells was 0.13±0.01g/l. (c) Comparison of enzyme levels and fold improvement of 1,2-PD in cells carrying different (1:2:1)n
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zymes, giving rise to a bidirectional pathway arrangement
(Figure 1b). To determine the impact of these designs,
E. coli cells were transformed with plasmids encoding
the ZF-enzyme chimeras and the different scaffolds.
Nearly all of the scaffolds with 12-bp spacers between
ZF binding sites were observed to enhance 1,2-PD pro-
duction (Figure S5a). In particular, the [1:1:1]4, [1:1:1]8,
[1:2:1]4, [1:2:2]4, and [1:4:2]2 scaffolds each increased
1,2-PD levels by  4-5 fold compared to the
unscaffolded control. These data also revealed that when
only a single scaffold unit was present (n=1), product
titers were largely insensitive to the scaffold stoichiometry.
However, as the number of scaffold units was increased,
the effect of scaffold stoichiometry on 1,2-PD levels
became more varied. We also observed that nearly all scaf-
folds with 4-bp spacers between ZF binding sites were less
effective than their 12-bp counterparts at improving
1,2-PD titers (Figure S5b).
To investigate the factors underlying the observed en-
hancement of 1,2-PD production, we ﬁrst measured the
cellular expression levels of ZF-enzyme chimeras in the
presence of different DNA scaffolds. Regardless of
whether the cells carried a (1:2:1)n scaffold, a random
scaffold sequence or lacked a scaffold altogether, the ex-
pression level of these chimeras were all very similar with
the exception of cells carrying the (1:2:1)2 and (1:2:1)4
scaffolds, which appeared to accumulate slightly
lower levels of MgsA-ZFa and DkgA-ZFb enzymes
(Figure 3c). However, this lower expression on it’s own
was insufﬁcient to explain the improved 1,2-PD titers
conferred by these scaffolds. This is because the (1:2:1)1
and the (1:2:1)8 scaffolds showed similar enhancements in
1,2-PD titers but with enzyme expression levels that were
nearly indistinguishable from the unscaffolded controls.
Therefore, we conclude that a simple change in cellular
enzyme levels is not the cause of the DNA scaffold-guided
enhancement of 1,2-PD levels. To test whether enzyme
proximity was important for enhanced 1,2-PD titers, the
ZF binding sites within the (1:2:1)2 scaffold were separated
on the plasmid by  1000bp. As seen above for resveratrol
production, the enhancement in 1,2-PD production was
abolished when the binding sites for each enzyme were
positioned far apart on the plasmid (Figure 3c). Hence,
the relative proximity of the enzymes appears to be a key
factor underlying the observed titer enhancements.
Extending DNA scaffolds to mevalonate production
As a ﬁnal test of the generality of our approach, we at-
tempted to use DNA scaffolds to improve mevalonate
production. We chose this pathway because production of
mevalonate from acetyl-CoA in E. coli has been described
(Figure 4a) (35). Furthermore, as mentioned above, previ-
ous studies demonstrated that assembly of the mevalonate
biosynthetic enzymes on a protein scaffold caused cells to
accrue signiﬁcantly higher titers of mevalonate (14); there-
fore, this pathway allows direct comparison between our
DNA scaffolds and earlier protein-based scaffolds. We
created ZF-enzyme chimeras by fusing the mevalonate bio-
synthetic enzymes E. coli acetoacetyl-CoA thiolase (AtoB),
Saccharomyces cerevisiae hydroxy-methylglutaryl-CoA
synthase (HMGS) and S. cerevisiae hydroxy-
methylglutaryl-CoA reductase (HMGR) to the
N-termini of ZFa, ZFb and ZFc, respectively. For the
scaffold design, target DNA sequences corresponding to
each of the ZF domains were placed on a separate
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Figure 4. DNA scaffold-assisted production of mevalonate. (a)
Schematic representation of mevalonate biosynthetic pathway. (b)
Comparison of enzyme levels and mevalonate titers from E. coli cells
expressing the AtoB-ZFa, HMGS-ZFb and HMGR-ZFc chimeras in
the presence of (1:2:2)n scaffolds with n=1, 2, 4, 8 or 16 and the
spacing between ZF binding sites=12bp as indicated. Cells expressing
the ZF-enzyme chimeras in the presence of the random scaffold control
served as the control to which all data were normalized. The amount of
mevalonate produced in the random scaffold control cells was
1.7±0.07g/l. Data are the average of three replicate experiments and
error bars are the standard error of the mean (SEM).
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above, mevalonate titers were increased 2- to 3-fold
in the presence of several different scaffold designs
(Figure S6a). While no clear trend was apparent, the
greatest titer enhancement—an increase of nearly
3-fold—came from the (1:4:2)16 scaffold. This was
followed closely by several of the (1:2:2)n scaffolds (i.e.
n=2, 4 and 16) that each enhanced mevalonate titers by
 2.5 fold compared to the random scaffold control
(Figure 4b). The fact that the best yield enhancement
using protein-based scaffolds also came from a 1:2:2
motif (14) suggests that this arrangement may be
optimal for balancing pathway ﬂux. Consistent with the
results above for 1,2-PD, the smaller 4-bp spacers
between the ZF binding sites resulted were less effective
than their 12-bp counterparts at improving metabolic
performance (Supplementary Figure S6b). In fact, most
scaffolds containing 4-bp spacers resulted in little to no
enhancement of mevalonate titers compared to un-
scaffolded enzymes. Finally, while the expression levels
of the ZF-enzyme chimeras were largely unaffected by
the presence or absence of a speciﬁc DNA scaffold, the
amount of AtoB-ZFa that accumulated in cells was much
greater compared to the HMGS-ZFb/HMGR-ZFc
chimeras (Figure 4b). In contrast, the expression levels
of the ZF-enzyme chimeras for 1,2-PD were more evenly
balanced, which might account for the generally larger
fold improvements seen for the production of 1,2-PD
versus mevalonate. These data suggest that more
balanced expression of the ZF-enzyme chimeras may
further increase mevalonate titers in the future.
DISCUSSION
We have demonstrated DNA scaffold-assisted biosynthe-
sis as a viable strategy for signiﬁcantly enhancing the titers
of three diverse metabolic products. This enhancement
appears to arise from the enforced proximity of metabolic
enzymes that likely increases the effective concentrations
of intermediary metabolites. In every case tested, DNA
scaffold-assisted biosynthesis was implemented on an
existing microbial metabolic pathway and did not
require any a priori knowledge about the structure or
function of any of the underlying biosynthetic enzymes,
making the implementation of this new approach simple
and generalizable to virtually any pathway. This was made
possible by the ability to fuse distinct ZF domains to
diverse protein targets at will without signiﬁcant loss of
the ZF domains’ DNA binding activity or the target
proteins’ enzymatic activity. As a result, this is the ﬁrst
ever report of DNA as an intracellular scaffold for
controlling the ﬂow of information in a metabolic or sig-
naling context.
It should be pointed out that scaffolds comprised of
comprising expressed proteins and RNAs have recently
been reported that have been used for directing new cell
signaling behaviors (24,36) and linking together metabolic
enzymes to more efﬁciently synthesize desired chemical
products (14,15). Compared to these systems, DNA scaf-
folds present a number of unique challenges and
opportunities for improvement. For example, much
larger titer enhancements were observed with both
protein- and RNA-based scaffolds (>50-fold) compared
to DNA scaffolds (up to  5-fold). In the case of protein
scaffolds, however, the largest titer enhancements
(77-fold) were observed only under conditions where
enzyme expression levels were very low. When saturating
amounts of the inducer were used, which were on par with
the inducer concentration used in our studies (i.e.
 250nM anhydrotetracycline), the scaffold-dependent
increases in mevalonate titers decreased to levels that
were similar to or even below those observed here.
Furthermore, when protein scaffolds were applied to a
second metabolic system, namely glucaric acid produc-
tion, the improvement was  2–5 fold (14,37), which was
consistent with the improvements achieved with DNA
scaffolds. In the case of RNA scaffolds, studies were
focused on just a single metabolic system, namely bio-
hydrogen production. Thus, whether such a large titer en-
hancement can be generalized to other pathways
remains to be shown. A potential drawback of DNA scaf-
folds is that the placement of repetitive sequences
in plasmid DNA may result in recombination of the
plasmid to remove the repeat regions. To date, however,
we have performed numerous DNA sequencing and re-
striction digestion analysis experiments and have never
seen evidence of plasmid recombination under any of
the conditions tested. Nonetheless, a recA
  strain back-
ground in which recombination events are minimized
could be used as the scaffolding host. Another challenge
associated with plasmid DNA is its tendency to become
supercoiled in cells. Plasmid supercoiling may restrict
the ability to spatially control enzyme orientation espe-
cially over long distances. In contrast, the use of
RNA permits the assembly of discrete one- and two-
dimensional scaffolds (15). However, with the recent de-
velopment of methods for rationally designing DNA
nanostructures with complex secondary structures that
assemble in the cytoplasm of E. coli (38), it may be
possible in the future to create nanostructured DNA scaf-
folds in vivo that permit exquisite patterning of target
proteins.
Despite some of these challenges, the ultra-stable nature
of DNA and its ability to support locally ordered scaf-
folds, here up to 2.4kb with over 150 individual ZF
binding sites, will enable scalability of DNA scaffolds to
large metabolic systems (i.e. comprising more than three
enzymes and/or more than one pathway) arranged in vir-
tually any stoichiometry and repeated many times over.
Another major advantage of DNA scaffolds is their modu-
larity, which permits a very high degree of freedom with
respect to important system variables such as: stoichiom-
etry of enzyme binding sites, number of scaffold units (n),
spacing of ZF binding sites, location of binding sites on
the plasmid, copy number of the plasmid, and binding
afﬁnity of the ZF domain for the DNA target sequence.
The number of tunable parameters that can be used to
advantageously tailor a metabolic system increases dra-
matically if one also considers the range of modiﬁcations
that can be made to the ZF-enzyme fusion (e.g. N- or
C-terminal attachment of ZF domain, length and
Nucleic Acids Research,2012, Vol.40, No. 4 1887composition of the linker connecting ZF domain to the
enzyme, sequence of the ZF domain, etc.). By studying
different DNA scaffold architectures, enzyme
stoichiometries, and ﬂux balanced or imbalanced scen-
arios, it should be possible to determine when enzyme
co-localization is most beneﬁcial. This, in turn, will be
very useful for guiding future design of these systems
and in envisioning new applications for enzyme
co-localization. It is also worth mentioning that our
DNA scaffold approach is highly complementary to
many of the existing methods for enzyme, pathway
and strain engineering that are already in the cellular en-
gineer’s toolkit. Hence, a successful strategy for achieving
the production yields, near theoretical maximum, neces-
sary for industrial viability will likely involve a combin-
ation of these approaches. Of course, DNA scaffolds
could also be used to ﬂexibly control the ﬂow of different
classes of biological information that extend beyond meta-
bolic pathways and small-molecule products. For
example, DNA scaffolds could be used to rewire intracel-
lular signaling pathways or to coordinate other
assembly-line processes such as protein folding, degrad-
ation and post-translational modiﬁcations. Thus, we an-
ticipate that DNA scaffolds should enable the
construction of reliable protein networks to program a
range of useful cellular behaviors. Even though the
beauty of nature’s most elegant compartmentalization
strategies such as a protected tunnel (4) or intracellular
organelles (8,9) have yet to be recapitulated by engineers,
the use of DNA scaffolds is an important early step
towards this goal.
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